



RNS Trading Statement

## Trading Update

### EMIS GROUP PLC

Released 07:00:03 08 July 2022

RNS Number : 7526R  
EMIS Group PLC  
08 July 2022

**8 July 2022**

**EMIS Group plc**  
**("EMIS Group" or "the Group")**

### **Trading update**

EMIS Group plc (AIM: EMIS.L), a UK leader in connected healthcare software and systems, today announces a trading update for the six months ended 30 June 2022.

Trading for the half year continued to track in line with the Board's expectations. The Group retained its leading positions in specialist markets, benefited from high levels of recurring revenue and remained in a strong financial position.

In **EMIS Health**, the Group is continuing to support its customers across the NHS while accelerating investment in its technology and cloud refresh strategy as well as in improved internal systems. As expected, revenue growth was held back by a planned reduction in lower margin resale partner activities. However, the business will benefit from a number of digitisation contracts which were secured for delivery in the second half of the year.

In **EMIS Enterprise**, the Group continues to execute in the areas of analytics, patient-facing services and pharmacy, with encouraging contributions from the two acquisitions completed in the period adding to double digit organic growth in revenues in the first half.

The Group retains a strong balance sheet position with net cash at 30 June 2022 of £53.6m (30 June 2021: £48.0m).

### **For further information, contact:**

#### **EMIS Group plc**

Andy Thorburn, CEO

Peter Southby, CFO

[www.emisgroupplc.com](http://www.emisgroupplc.com)

@EMISGroup

**Tel: 0330 024 1269****Numis Securities Limited (Nominated Adviser & Broker)****Tel: 020 7260 1000**

Joshua Hughes/Simon Willis/James Black

**MHP Communications**

Reg Hoare/Matthew Taylor/Pauline Guenot

**Tel: 020 3128 8567****emis@mhpc.com**

Information for investors can be found on the Group's website at [www.emisgroupplc.com/investors](http://www.emisgroupplc.com/investors).

**Notes to Editors**

EMIS Group has grown to become a UK leader in connected healthcare software and systems. Its solutions are widely used across a number of major UK healthcare settings. EMIS Group's aim is to join up healthcare through innovative technology, helping to deliver better health outcomes to the UK population, supporting longer and healthier lives.

EMIS Group has two core business segments: EMIS Health and EMIS Enterprise.

EMIS Health is a supplier of innovative integrated care technology to the NHS, including primary, community, acute and social care.

EMIS Enterprise is focussed on growth in the business-to-business technology sector within the healthcare market, including management of medicines, partner businesses, patient-facing services, data and analytics, and research and life sciences.

LEI: 213800K474ZZK76NX913

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TSTUPUQCMUPPGAM

---

**London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.**

---

© 2022 London Stock Exchange plc. All rights reserved.